Investors in Bayer are currently evaluating the necessity of a cash call to alleviate the burden of the company's significant debt load. The pharmaceutical and life sciences company has been facing challenges related to its debt obligations, prompting stakeholders to consider potential solutions.
Bayer's debt levels have been a point of concern for investors, as the company grapples with the need to address its financial liabilities. The possibility of a cash call, which involves raising additional funds through the issuance of new shares or debt instruments, is being weighed as a potential strategy to manage the debt effectively.
